Journal of the Formosan Medical Association, 2022 Background: Whether immunocompromising conditions affect the immunogenicity of COVID-19 booster vaccination remains a concern, which impedes the vaccination campaign in people most vulnerable to COVID-19-associated morbidity and mortality.
Kuan-Yin Lin +6 more
doaj +1 more source
Adverse Effects of Third-Dose Moderna Vaccination for Healthcare Workers of Udayana University Hospital, Bali, Indonesia [PDF]
, 2022 . Background Since its first sighting in China at the end of 2019, COVID-19 had spread rapidly around the world, with no exception, to Indonesia. World Health Organization officially declared COVID-19 as a pandemic in March 2020.
Cokorda Agung Wahyu Purnamasidhi +8 more
core +2 more sources
Impact of Holding Immunosuppressive Therapy in Patients with Inflammatory Bowel Disease Around mRNA COVID-19 Vaccine Administration on Humoral Immune Response and Development of COVID-19 Infection [PDF]
, 2023 BACKGROUND AND AIMS: The BNT162b2 and mRNA-1273 COVID-19 vaccines are efficacious in patients with inflammatory bowel disease; but there is a lack of data examining if holding immunosuppressive therapy around vaccination improves immune response.
Cross, Raymond K +7 more
core +2 more sources
Analysis of the adverse events following the mRNA-1273 COVID-19 vaccine [PDF]
, 2023 OBJECTIVE: This study aims to characterize the adverse events (AEs) following the administration of the mRNA-1273 COVID-19 vaccine from the Vaccine Adverse Event Reporting System (VAERS) data.METHODS: In this case/non-case analysis, reports between 1 ...
Nishtala, Prasad S, Shabu, Angel
core +1 more source
Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review
Expert Review of Vaccines, 2023 Introduction Current safety data from Phase 3 clinical trials have concluded that apart from transient local and systemic reactions, no safety concerns were identified for the Moderna COVID-19 vaccine (mRNA-1273).
Angel Shabu, Prasad S. Nishtala
doaj +1 more source
Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines
Microbiology Spectrum, 2021 Studies examining antibody responses by vaccine brand are lacking and may be informative for optimizing vaccine selection, dosage, and regimens. The purpose of this study is to assess IgG antibody responses following immunization with BNT162b2 (30 μg ...
José G. Montoya +9 more
doaj +1 more source
Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial [PDF]
, 2022 This cohort study assesses the durability of protection against symptomatic COVID-19 among participants of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine ...
Baden, Lindsey R. +7 more
core +2 more sources
Risk of myocarditis following sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by age and sex [PDF]
, 2022 Myocarditis is more common after severe acute respiratory syndrome coronavirus 2 infection than after COVID-19 vaccination, but the risks in younger people and after sequential vaccine doses are less certain.
Channon, Keith M +13 more
core +1 more source
Hypersensitivity to the Moderna COVID-19 vaccine caused by tromethamine: PEG is not always the culprit excipient [PDF]
, 2022 Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are considered the cornerstone of the solution to the current global pandemic.
Cernada, J +4 more
core +1 more source
Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2) [PDF]
, 2023 Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%-98.7%]) compared to Pfizer-BioNTech BNT162b2 ...
Abela, Irene A +25 more
core +7 more sources